Market Cap: $240.34M
VI
Vanda Pharmaceuticals Inc.
VNDA
NASDAQ (NASDAQ Global Market)USD
Market Cap: $240.34M
Vanda Pharmaceuticals Advocates For Improved FDA Guidance on Animal Testing Alternatives Vanda Pharmaceuticals Inc., a prominent player in the realm of innovative drug development, expresses grave con…
Vanda Pharmaceuticals Voices Concerns Over FDA's New Draft Guidance on Drug Development Vanda Pharmaceuticals Inc., a prominent player in innovative drug development, recently raises serious objection…
Vanda Pharmaceuticals Secures Rare FDA Hearing for HETLIOZ® on Jet Lag Disorder Vanda Pharmaceuticals Inc. faces a significant regulatory milestone as the U.S. Food and Drug Administration (FDA) grant…
Vanda Pharmaceuticals Seeks Clarity in Jet Lag Treatment Approval Process Vanda Pharmaceuticals Inc. achieves a significant procedural milestone as the U.S. Food and Drug Administration (FDA) grants i…
Vanda Pharmaceuticals Showcases Commitment to Innovation at Upcoming Life Sciences Conference Vanda Pharmaceuticals Inc. is set to participate in the 2026 Citizens Life Sciences Conference in Miami, h…
Vanda Pharmaceuticals' Innovative Approach to Generalized Pustular Psoriasis Treatment Vanda Pharmaceuticals Inc. shines a spotlight on its commitment to addressing rare inflammatory diseases with the…
Vanda Pharmaceuticals Advances Mental Health Care with FDA Approval of Bysanti The FDA's recent approval of Bysanti marks a significant advancement in Vanda Pharmaceuticals' commitment to addressing m…
Vanda Pharmaceuticals Gains FDA Approval for Bysanti: A New Hope for Bipolar Disorder and Schizophrenia Treatment Vanda Pharmaceuticals (NASDAQ: VNDA) makes headlines with the U.S. Food and Drug Admin…
Vanda Pharmaceuticals' Major Regulatory Approval: A Game-Changer for Bipolar I Disorder and Schizophrenia Treatment Vanda Pharmaceuticals (NASDAQ:VNDA) receives a major boost as the U.S. Food and Drug…
Vanda Pharmaceuticals Secures FDA Approval for Bysanti, Elevating Treatment Options for Bipolar Disorder and Schizophrenia Vanda Pharmaceuticals (NASDAQ:VNDA) announces a significant advancement in it…
FDA’s Rejection of HETLIOZ® Sparks Ongoing Dispute for Vanda Pharmaceuticals Vanda Pharmaceuticals Inc. faces a significant setback following the U.S. Food and Drug Administration's (FDA) rejection of…
Vanda Pharmaceuticals Strengthens Position in Motion Sickness Treatment with FDA Approval Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) achieves a significant milestone with the FDA's recent approval of i…
Vanda Pharmaceuticals' Nereus Approval Marks a Breakthrough in Motion Sickness Treatment Vanda Pharmaceuticals Inc. achieves a significant milestone with the recent approval of its drug Nereus (tradip…
Vanda Pharmaceuticals Navigates Market Sentiment Amid Economic Uncertainty Vanda Pharmaceuticals faces a challenging landscape as it operates within the broader context of fluctuating market sentiment…
Vanda Pharmaceuticals Expands Portfolio with FDA Approval of Motion Sickness Drug Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) achieves a significant milestone with the recent FDA approval of its new dru…
Vanda Pharmaceuticals Expands Portfolio with FDA Approval of NEREUS Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) celebrates a significant milestone with the recent approval from the U.S. Food and Drug Ad…
Vanda Pharmaceuticals Celebrates FDA Approval of NEREUS, Expanding Its Therapeutic Portfolio Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) achieves a significant milestone with the recent FDA approval of…
Vanda Pharmaceuticals Advances Treatment Options for Rare Skin Condition Vanda Pharmaceuticals Inc. makes a significant stride in the treatment of rare inflammatory skin disorders with the recent subm…
Vanda Pharmaceuticals Advances Treatment for Rare Skin Condition with New BLA Submission Vanda Pharmaceuticals Inc. takes a significant step in the field of dermatology with the recent submission of a…
Vanda Pharmaceuticals Advances Treatment for Rare Skin Condition with BLA Submission Vanda Pharmaceuticals Inc. takes a significant step forward in the treatment of generalized pustular psoriasis (GPP…
FDA Lifts Clinical Hold on Vanda Pharmaceuticals' Tradipitant Development Vanda Pharmaceuticals Inc. achieves a significant milestone as the U.S. Food and Drug Administration (FDA) lifts the partial c…
Vanda Pharmaceuticals Receives FDA Approval to Expand Clinical Use of Tradipitant Vanda Pharmaceuticals Inc. announces a significant milestone in its clinical development journey as the U.S. Food and…
Vanda Pharmaceuticals Secures FDA Approval to Advance Tradipitant for Motion Sickness Treatment Vanda Pharmaceuticals Inc. announces a significant milestone in its clinical development program for tra…
Innovative Advances in Motion Sickness Treatment: Vanda Pharmaceuticals' Tradipitant Under FDA Review Vanda Pharmaceuticals Inc. is making strides in the realm of motion sickness treatment with its dr…
Vanda Pharmaceuticals Advances Tradipitant for Motion Sickness Vanda Pharmaceuticals Inc. is making significant strides in the development of tradipitant, a potential treatment for motion sickness, as…